China-based HutchMed (NASDAQ: HCM, HKG: 0013) released its 2024 financial report, revealing a total revenue of USD 630.2 million, marking a 25% year-on-year decline. The oncology/immune business segment reported USD 363.4 million, a decrease of 31% compared to the previous year.
Oncology Product Performance
Despite the overall decline, oncology product sales saw a significant increase of 67% to USD 271.5 million. This growth was largely driven by the strong performance of Fruzaqla (fruquintinib’s global brand name), partnered with Takeda for markets outside China. Fruzaqla generated USD 290.6 million, fueled by its acceptance in the US market and launches in over ten countries worldwide. The milestone of reaching USD 200 million in sales triggered a USD 20 million milestone payment from Takeda. For the full year, HutchMed received USD 67 million in upfront payments, regulatory milestones, and R&D services from Takeda.
Elunate’s Market Leadership
Elunate, the Chinese brand name for fruquintinib, maintained its position as the leader in metastatic colorectal cancer with in-market sales increasing by 9% year-on-year to USD 115 million. The drug received approval for a new indication from the National Medical Products Administration (NMPA) in December 2024 for the treatment of endometrial cancer.
Other Products
Sulanda (surufatinib) saw its in-market sales rise by 12% year-on-year to USD 49 million, while Orpathys (savolitinib) recorded USD 45.5 million for the full year, unchanged from the previous year.-Fineline Info & Tech
Leave a Reply